` NEO (Neogenomics Inc) vs S&P 500 Comparison - Alpha Spread

NEO
vs
S&P 500

Over the past 12 months, NEO has underperformed S&P 500, delivering a return of -47% compared to the S&P 500's 9% growth.

Stocks Performance
NEO vs S&P 500

Loading
NEO
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
NEO vs S&P 500

Performance Gap Between NEO and GSPC
HIDDEN
Show

Performance By Year
NEO vs S&P 500

Loading
NEO
S&P 500
Add Stock

Competitors Performance
Neogenomics Inc vs Peers

S&P 500
NEO
0KHE
TMO
DHR
207940
Add Stock

Neogenomics Inc
Glance View

Market Cap
892.1m USD
Industry
Life Sciences Tools & Services

NeoGenomics Inc. stands as a formidable player in the field of cancer diagnostics, carving out a niche where precision and innovation meet the urgent needs of patients and healthcare providers. Born out of the vision to advance cancer diagnostics through a blend of clinical testing and state-of-the-art technology, NeoGenomics offers oncologists and pathologists an extensive menu of tests that target genetic markers critical for cancer diagnosis and monitoring. The company operates through a network of high-complexity laboratories in the United States and a growing presence internationally, leveraging its vast technological capabilities to provide services like cytogenetics, molecular testing, and solid tumor testing. This breadth of service allows NeoGenomics to sit squarely at the intersection of patient care and the burgeoning field of personalized medicine. By anchoring its revenue streams primarily in laboratory services, NeoGenomics draws its financial strength from a diverse clientele of community-based healthcare providers, academic institutions, and pharmaceutical companies. The firm capitalizes on the demand for precision diagnostics, as more treatments necessitate an intimate understanding of the tumor’s genetic makeup. This careful calibration between cutting-edge science and clinical practice not only fuels its growth but also positions NeoGenomics as an indispensable partner in the continuum of cancer care. Additionally, its collaborations with pharmaceutical companies open doors to new revenue channels via companion diagnostic development and clinical trial support services, exemplifying an agile approach in the dynamic landscape of oncology.

NEO Intrinsic Value
HIDDEN
Show
Back to Top